Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;127(5):837-847.
doi: 10.1097/AOG.0000000000001396.

Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival

Laura Power  1 , Georgia Lefas, Pascal Lambert, Diane Kim, Debra Evaniuk, Robert Lotocki, Erin Dean, Mark W Nachtigal, Alon D Altman
Affiliations

Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival

Laura Power et al. Obstet Gynecol. 2016 May.

Abstract

Objective: To evaluate whether hormone therapy (HT) after nonserous epithelial ovarian cancer is associated with a decrease in overall and disease-free survival.

Methods: We conducted a retrospective cohort study. The Manitoba Cancer Registry and Drug Programs Information Network were searched to find all women with known nonserous epithelial ovarian, fallopian tube, or primary peritoneal cancer between 1995 and 2010 who had used HT after treatment. Women who did not receive treatment or had no follow-up were excluded.

Results: Three hundred ninety-one patients met the inclusion criteria. Seventeen patients were excluded because the patients did not receive treatment for cancer, and 17 were excluded for lack of follow-up. A total of 94 women received HT after treatment, and 263 women did not. The average age was 57.8 years. In HT users younger than 55 years of age, disease-free survival is improved according to both the multivariable landmark analysis (n=68/145, adjusted hazard ratio 0.354, 95% confidence interval [CI] 0.17-0.74, P=.006) and the time-varying Cox regression analysis (n=42/158, adjusted hazard ratio 0.212, 95% CI 0.07-0.60, P=.004) when adjusting for International Federation of Gynecology and Obstetrics stage and need for chemotherapy. There is no statistical difference in overall survival in this age group. No associations between HT use and overall survival or disease-free survival were found among women aged 55 years and older.

Conclusion: After treatment for nonserous epithelial ovarian cancer, hormone therapy is not associated with decreased disease-free or overall survival.

PubMed Disclaimer

References

    1. Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, et al.. Ovarian failure following cancer treatment: current management and quality of life. Hum Reprod 2008;23:2506–12.
    1. King J, Wynne CH, Assersohn L, Jones A. Hormone replacement therapy and women with premature menopause—a cancer survivorship issue. Eur J Cancer 2011;47:1623–32.
    1. Wenzel LB, Donnelly JP, Fowler JM, Habbal R, Taylor TH, Aziz N, et al.. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 2002;11:142–53.
    1. Maclaran K, Horner E, Panay N. Premature ovarian failure: long-term sequelae. Menopause Int 2015;16:38–41.
    1. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257–71.

Publication types

LinkOut - more resources